IPSEN Aktie

 

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Information relating to the holding of the Combined Shareholders' Meeting of 13 May 2026 of Ipsen S.A....

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Ipsen (IPN.PA, I7G.F) announced that the European Commission has granted conditional marketing authorization for Ojemda as monotherapy for the treatment of pat......

PARIS, FRANCE, 22 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has granted conditional marketing authorization for Ojemda® (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade-glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies.ii This EC decision applies across all 27 EU Member States, as well as Iceland, Liechtenstein, and Norway....

Encouraging Phase 2 clinical activity with confirmed complete responses observed in heavily pretreated metastatic breast cancer across both TNBC and HR+/HER2- subtypes First public disclosure of clinical stage Ipsen-partnered STAR program IPN01203 CAMBRIDGE, Mass., April 17, 2026......

PARIS, FRANCE, 3 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) announces that Beech Tree — which directly and indirectly holds 26.03% of Ipsen S.A.'s share capital and 33.05% of its voting rights — has obtained from the French Financial Markets Authority (Autorité des marchés financiers) an exemption from the obligation to file a public tender offer for all Ipsen S.A. shares.1...

Ipsen announces the availability of its 2025 Universal Registration Document...

PARIS, FRANCE, 18 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR) congress. These latest data include an oral presentation for T cell activator (TCA) IPN01203 to be presented during the coveted New Drugs on the Horizon program session, highlighting the differentiated mode of action, activating Vβ6/Vβ10 T cells. These latest preclinical data will expand the growing evidence base, reinforcing the first-in-class potential of IPN01203 to improve outcomes where there are significant unmet needs for people living with solid tumors....

Monthly information relative to the total number of voting rights and shares composing the share capital...

NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas such ......

PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership Team (ELT) and will report directly to Ipsen's Chief Executive Officer (CEO), David Loew....

Hong Kong-listed Hutchmed Co. Ltd. is withdrawing its cancer treatment tazemetostat in Greater China less than a year after its commercial launch, following a decision by its partner Ipsen to pull the drug in the U.S. over safety concerns. ... Read more...

PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of secondary hematologic malignancies, the risks may outweigh potential benefits for patients within this treatment regimen. As a result of these data, Ipsen is withdrawing Tazverik effective immediately, including both for follicular lymphoma (FL) and epithelioid sarcoma (ES)....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology therapy licensed from Epizyme, Inc. (“Epizyme”), an Ipsen (“Ipsen”) company, in China. Epizyme is the Marketing Authorization Holder of TAZVERIK® in the Chinese mainland, for which HUTCHMED Limited (a subsidiary of the Company) acts as the domestic agent/licensee. Ipsen has informed HUTCHMED that it is voluntarily withdrawing TAZVERIK® in the US. As a result, steps have been taken to initiate the market withdrawal and product recall in China. Consequently, HUTCHMED Limited has initiated a withdrawal and product recall from the Chinese mainland, Hong Kong and Macau, and is discontinuing all active tazemetostat clinical trials. Existing patients should consult their treating physicians immediately to discuss their treatment options....

PARIS (dpa-AFX) - Ipsen (IPSEY, I7G.F) announced that it has voluntarily withdrawn Tazverik (tazemetostat) from all indications across its markets. The decision follows emerging data from the ongo......

PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of secondary hematologic malignancies, the risks may outweigh potential benefits for patients within this treatment regimen. As a result of these data, Ipsen is withdrawing Tazverik effective immediately, including both for follicular lymphoma (FL) and epithelioid sarcoma (ES)....

PARIS (dpa-AFX) - At its February 2026 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions for Moderna's combined COVID-19 -Influ......

PARIS, FRANCE, 27 FEBRUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the conditional marketing authorization of Ojemda® (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (pLGG) harbouring a BRAF fusion or rearrangement or BRAF V600 mutation, who have progressed after one or more prior systemic therapies.i...